.svg)
.svg)
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg){kind=icon}
.svg){kind=icon}
Publication date: December 16, 2024
- Year of founding: 1995
- Year added to the AEX: 2020
- Highest share price ever: €211.30 in December 2021
- Average trading volume: Circa 61.000 shares per day
- Share price performance over the past 12 months: - 5.45%
Introduction about the company
IMCD N.V. is a leading multinational distributor of specialty chemicals and food ingredients, headquartered in Rotterdam. The company is listed on Euronext Amsterdam under the symbol IMCD and is part of the AEX index. IMCD serves various sectors, including pharmaceuticals, food, personal care, and industrial applications, and provides customized distribution solutions to customers worldwide.
Core figures & performance
For the full year 2023, IMCD N.V. reported sales of €4.44 billion, down 3% from €4.60 billion in 2022. Profit was about €400 million, down about 7% compared with €430 million in the previous year. The workforce grew by almost 10% to 4,736 employees. IMCD's market capitalization is €8.61 billion in December 2024.
History & development
Founded in 1995, IMCD has evolved into a global player in the distribution of specialty chemicals and ingredients. The company has strengthened its presence through strategic acquisitions and recently acquired Blumos Group in October 2024 to accelerate growth in life sciences markets in Latin America. IMCD continues to focus on expanding its global footprint and diversifying its product portfolio.
Sector & competition
IMCD operates in the competitive specialty chemicals and food ingredients sector, with competitors such as Brenntag and Azelis. The industry requires constant innovation and adaptation to changing customer needs. IMCD is distinguished by its technical expertise, extensive product portfolio, and global network, which enables it to provide customized solutions to various industries.
Influence of IMCD on the AEX
IMCD, compared to the other chemical companies in the AEX, has the smallest influence on the index with a weighting of 0.79% (measured on June 28, 2024). This limited influence stems from the AEX's calculation method, which determines weighting based on market capitalization. As a result, IMCD's performance has only a modest effect on the overall movements of the AEX index.
Investment analysis & outlook
Analysts view IMCD as a solid investment due to its strong market position, diversified product portfolio, and global presence. Its focus on strategic acquisitions and market expansion offers growth potential. However, factors such as economic fluctuations, competitive pressure, and changing regulations can pose challenges. IMCD remains focused on strengthening its market position and delivering value to shareholders through continued growth and innovation.
The chart below compares Unilever's share price performance with the AEX index over the past 5 years. It shows that despite some fluctuations in the market, the company has remained relatively stable compared to five years ago. What is notable is that Unilever's share price performance shows similar movements to the AEX, although the AEX has experienced significantly greater growth. This is due in part to the strong performance of Tech funds and other large companies in the index.
News & updates
Recently, IMCD raised €300 million through accelerated book-building to increase its financial flexibility. In addition, the company continues to expand its global presence through strategic acquisitions in various regions and sectors. For more details on IMCD's financial performance and initiatives, please visit its official website: IMCD.com.
Disclaimer: Investing involves risk. Our analysts are not financial advisors. Always consult an advisor when making financial decisions. The information and tips provided on this website are based on our analysts' insights and experiences. As such, they are for educational purposes only.
.webp)
.webp)
.webp)
